Myriad Genetics Inc
MYGN
NASDAQ
Biotechnology
$3.03
USD
-0.14 (-4.42%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $307.03M
Volume 1.6M
Peer Comparison Table
(1/4) | ||||||
|---|---|---|---|---|---|---|
GALT | Galectin Therapeutics Inc | $347.93M | - | - | - | |
SABS | SAB Biotherapeutics Inc | $343.93M | 25.91 | - | - | |
TLSI | TriSalus Life Sciences Inc | $343.59M | - | +39.6% | - | |
FATE | Fate Therapeutics Inc | $326.37M | - | -52.6% | - | |
IKT | Inhibikase Therapeutics Inc | $324.80M | - | - | - | |
MYGN | Myriad Genetics Inc | $313.25M | - | -3.2% | - | |
AVXL | Anavex Life Sciences Corp | $311.92M | - | - | - | |
AGEN | Agenus Inc | $311.48M | 4.82 | +24.5% | - | |
IRD | Opus Genetics Inc | $304.50M | - | -12.2% | - | |
VNDA | Vanda Pharmaceuticals Inc | $293.20M | - | +8.2% | - |
Top Peer by Growth
Z Squared Inc (Delaware)
+2149.0% YoY Revenue
Best 1-Year Return
ALX Oncology Holdings Inc
+226.8% Return